DE602004030343D1 - Hcv-vakzin - Google Patents

Hcv-vakzin

Info

Publication number
DE602004030343D1
DE602004030343D1 DE602004030343T DE602004030343T DE602004030343D1 DE 602004030343 D1 DE602004030343 D1 DE 602004030343D1 DE 602004030343 T DE602004030343 T DE 602004030343T DE 602004030343 T DE602004030343 T DE 602004030343T DE 602004030343 D1 DE602004030343 D1 DE 602004030343D1
Authority
DE
Germany
Prior art keywords
epitope
hcv
vaccine
hcv vaccine
hotspot
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
DE602004030343T
Other languages
English (en)
Inventor
Michael Buschle
Juergen Frisch
Christoph Klade
Karen Lingnau
Wolfgang Zauner
Gerd Zettlmeissl
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Valneva Austria GmbH
Original Assignee
Intercell Austria AG
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Intercell Austria AG filed Critical Intercell Austria AG
Publication of DE602004030343D1 publication Critical patent/DE602004030343D1/de
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A61K39/29—Hepatitis virus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55511—Organic adjuvants
    • A61K2039/55516—Proteins; Peptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55511—Organic adjuvants
    • A61K2039/55561—CpG containing adjuvants; Oligonucleotide containing adjuvants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2770/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses positive-sense
    • C12N2770/00011—Details
    • C12N2770/24011—Flaviviridae
    • C12N2770/24211—Hepacivirus, e.g. hepatitis C virus, hepatitis G virus
    • C12N2770/24222—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2770/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses positive-sense
    • C12N2770/00011—Details
    • C12N2770/24011—Flaviviridae
    • C12N2770/24211—Hepacivirus, e.g. hepatitis C virus, hepatitis G virus
    • C12N2770/24234—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
DE602004030343T 2003-07-11 2004-07-09 Hcv-vakzin Active DE602004030343D1 (de)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
EP03450171 2003-07-11
EP04450062 2004-03-12
PCT/EP2004/007540 WO2005004910A2 (en) 2003-07-11 2004-07-09 Hcv vaccines

Publications (1)

Publication Number Publication Date
DE602004030343D1 true DE602004030343D1 (de) 2011-01-13

Family

ID=34066530

Family Applications (1)

Application Number Title Priority Date Filing Date
DE602004030343T Active DE602004030343D1 (de) 2003-07-11 2004-07-09 Hcv-vakzin

Country Status (11)

Country Link
US (3) US20070031446A1 (de)
EP (2) EP2275131A3 (de)
JP (2) JP4734241B2 (de)
CN (1) CN1822856B (de)
AT (1) ATE489967T1 (de)
AU (1) AU2004255456B2 (de)
CA (1) CA2530062A1 (de)
DE (1) DE602004030343D1 (de)
PL (1) PL1648502T3 (de)
TW (1) TWI358301B (de)
WO (1) WO2005004910A2 (de)

Families Citing this family (24)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2711670B1 (fr) 1993-10-22 1996-01-12 Pasteur Institut Vecteur nucléotidique, composition le contenant et vaccin pour l'immunisation à l'encontre d'une hépatite.
US6207646B1 (en) 1994-07-15 2001-03-27 University Of Iowa Research Foundation Immunostimulatory nucleic acid molecules
ATE464907T1 (de) 1999-02-17 2010-05-15 Csl Ltd Immunogene komplexe und methoden in bezug auf diese
AT408721B (de) 1999-10-01 2002-02-25 Cistem Biotechnologies Gmbh Pharmazeutische zusammensetzung enthaltend ein antigen
US20070031446A1 (en) * 2003-07-11 2007-02-08 Intercell Ag Hcv vaccines
AT410635B (de) * 2000-10-18 2003-06-25 Cistem Biotechnologies Gmbh Vakzin-zusammensetzung
US20040053880A1 (en) 2002-07-03 2004-03-18 Coley Pharmaceutical Group, Inc. Nucleic acid compositions for stimulating immune responses
US7807803B2 (en) 2002-07-03 2010-10-05 Coley Pharmaceutical Group, Inc. Nucleic acid compositions for stimulating immune responses
MXPA05004588A (es) 2002-10-29 2005-12-14 Coley Pharmaceutical Group Ltd Metodos y productos relacionados con el tratamiento y prevencion de infeccion de virus de hepatitis c.
AU2003300919A1 (en) 2002-12-11 2004-06-30 Coley Pharmaceutical Gmbh 5' cpg nucleic acids and methods of use
DE602005004014T2 (de) * 2004-03-12 2008-12-11 Intercell Ag Verfahren zur solubilisierung von peptid-mischungen
EP1804822B1 (de) * 2004-10-29 2009-07-22 Intercell AG Hcv impfstoff für chronische hcv patienten
CA2601400A1 (en) * 2005-03-19 2006-09-28 Medical Research Council Improvements in or relating to treatment and prevention of viral infections
CN101426514A (zh) * 2006-04-25 2009-05-06 英特塞尔股份公司 Hcv疫苗
MX2009003398A (es) 2006-09-27 2009-08-12 Coley Pharm Gmbh Analogos de oligonucleotidos cpg que contienen analogos t hidrofobos con actividad inmunoestimuladora mejorada.
WO2010039195A2 (en) * 2008-09-23 2010-04-08 The Board Of Trustees Of The Leland Stanford Junior University Screening for inhibitors of hcv amphipathic helix (ah) function
WO2010054446A1 (en) * 2008-11-11 2010-05-20 Ademovic Zlatko Combination of two or more peptides in a single stable lyophilized pharmaceutical compound
BRPI1009801A2 (pt) * 2009-03-30 2016-03-15 Biomerieux Sa suporte sólido para detecção do hcv
WO2010148117A1 (en) 2009-06-17 2010-12-23 Scantibodies Laboratory, Inc. Therapeutic and diagnostic affinity purified specific polyclonal antibodies
EP2484378A4 (de) 2009-09-30 2013-05-22 Toray Industries Hepatitis-c-virus-impfstoffzusammensetzung
US8765148B2 (en) 2010-02-19 2014-07-01 Valneva Austria Gmbh 1C31 nanoparticles
US9752494B2 (en) 2013-03-15 2017-09-05 Kohler Co. Noise suppression systems
AU2018256867A1 (en) 2017-04-27 2019-11-14 The Johns Hopkins University Nucleoside-modified mRNA-lipid nanoparticle lineage vaccine for hepatitis C virus
CN109212220B (zh) * 2018-09-21 2021-06-29 北京凯因科技股份有限公司 丙型肝炎病毒抗体快速检测试纸条

Family Cites Families (35)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5683864A (en) * 1987-11-18 1997-11-04 Chiron Corporation Combinations of hepatitis C virus (HCV) antigens for use in immunoassays for anti-HCV antibodies
DE3834729A1 (de) * 1988-10-12 1990-04-19 Behringwerke Ag Verwendung von zink-oder eisenhydroxid zur adjuvierung von antigenloesungen und auf diese weise adjuvierte antigenloesungen
US5562910A (en) * 1989-09-25 1996-10-08 University Of Utah Research Foundation Vaccine compositions and method for enhancing an immune response
EP1227323B2 (de) 1990-08-25 2011-01-19 Bioprocess Pty Ltd Nicht-A, nicht-B Hepatitis Virus Antigen, und diagnostische Verfahren.
CA2110058C (en) * 1991-06-24 2001-09-25 David Y. Chien Hepatitis c virus (hcv) polypeptides
US6419931B1 (en) 1991-08-26 2002-07-16 Epimmune Inc. Compositions and methods for eliciting CTL immunity
US20030152580A1 (en) * 1994-07-21 2003-08-14 Alessandro Sette Hla binding peptides and their uses
US5333965A (en) 1992-01-31 1994-08-02 Mailey John W In situ modular fastening system
CN1118572A (zh) 1993-03-05 1996-03-13 萨依特尔有限公司 Hla-a2.1组合肽及其用途
US7157226B1 (en) 1993-04-27 2007-01-02 Innogenetics S.A. Sequences of hepatitis C virus genotypes and their use as therapeutic and diagnostic agents
US5709995A (en) 1994-03-17 1998-01-20 The Scripps Research Institute Hepatitis C virus-derived peptides capable of inducing cytotoxic T lymphocyte responses
CA2187299A1 (en) 1994-04-08 1995-10-19 Jay A. Berzofsky Hepatitis c virus core peptide for stimulation of cytotoxic t lymphocytes and diagnosis of hcv exposure
AUPM543894A0 (en) * 1994-05-04 1994-05-26 Commonwealth Scientific And Industrial Research Organisation An adjuvant
RS50101B (sr) 1996-02-24 2009-01-22 Boehringer Ingelheim International Gmbh., Farmaceutski preparati za imunomodulaciju
US6231859B1 (en) * 1996-12-02 2001-05-15 Aquila Biopharmaceuticals, Inc. Saponin adjuvant compositions
EP0855184A1 (de) * 1997-01-23 1998-07-29 Grayson B. Dr. Lipford Pharmazeutisches Präparat das ein Polynukleotid und ein Antigen enthält, insbesondere zur Impfung
ES2278411T3 (es) * 1997-05-01 2007-08-01 Protechtion Unlimited, Inc. Factor de crecimiento nervioso como adyuvante de vacuna.
DE19803453A1 (de) 1998-01-30 1999-08-12 Boehringer Ingelheim Int Vakzine
DE69935599T2 (de) 1998-08-21 2007-11-29 The Government Of The United States Of America As Represented By The Secretary, Department Of Health And Human Services Modifizierte hcv peptid-impfstoffe
WO2001021189A1 (en) * 1999-07-19 2001-03-29 Epimmune Inc. Inducing cellular immune responses to hepatitis c virus using peptide and nucleic acid compositions
US20090130135A1 (en) * 1999-10-01 2009-05-21 Michael Buschle Hcv vaccines
US20070031446A1 (en) * 2003-07-11 2007-02-08 Intercell Ag Hcv vaccines
AT408721B (de) 1999-10-01 2002-02-25 Cistem Biotechnologies Gmbh Pharmazeutische zusammensetzung enthaltend ein antigen
AT409085B (de) * 2000-01-28 2002-05-27 Cistem Biotechnologies Gmbh Pharmazeutische zusammensetzung zur immunmodulation und herstellung von vakzinen
EP1272215B1 (de) 2000-04-14 2007-10-10 Intercell AG Modifizierte peptide enthaltende pharmazeutische präparationen
ES2206424T3 (es) * 2000-06-08 2004-05-16 Intercell Biomedizinische Forschungs- Und Entwicklungs Ag Oligodesoxinucleotidos inmunoestimulantes.
WO2002013857A2 (en) 2000-08-17 2002-02-21 Intercell Biomedizinische Forschungs- Und Entwicklungs Ag A vaccine which comprises at least one antigen and a cathelididin derived antimicrobial peptide or a derivative thereof
AT410635B (de) * 2000-10-18 2003-06-25 Cistem Biotechnologies Gmbh Vakzin-zusammensetzung
AR045702A1 (es) * 2001-10-03 2005-11-09 Chiron Corp Composiciones de adyuvantes.
US6588670B2 (en) * 2001-10-30 2003-07-08 Symbol Technologies, Inc. Medical diagnostic monitoring
JP2005519035A (ja) * 2001-12-07 2005-06-30 インターツェル・アクチェンゲゼルシャフト 免疫促進性オリゴデオキシヌクレオチド
FR2843115B1 (fr) * 2002-08-02 2007-11-09 Commissariat Energie Atomique Melange de peptides issus des proteines c et ns3 du virus de l'hepatite c et leurs applications
CA2484339A1 (en) 2002-09-13 2004-03-25 Intercell Ag Method for isolating hepatitis c virus peptides
US7704514B2 (en) * 2003-03-24 2010-04-27 Intercell Ag Vaccines
EP1804822B1 (de) * 2004-10-29 2009-07-22 Intercell AG Hcv impfstoff für chronische hcv patienten

Also Published As

Publication number Publication date
US20110300170A1 (en) 2011-12-08
WO2005004910A2 (en) 2005-01-20
PL1648502T3 (pl) 2011-05-31
US20090155294A1 (en) 2009-06-18
AU2004255456B2 (en) 2010-06-24
ATE489967T1 (de) 2010-12-15
JP2009513542A (ja) 2009-04-02
CA2530062A1 (en) 2005-01-20
EP2275131A3 (de) 2012-01-25
CN1822856B (zh) 2010-04-28
TWI358301B (en) 2012-02-21
WO2005004910A3 (en) 2005-04-21
EP1648502B1 (de) 2010-12-01
CN1822856A (zh) 2006-08-23
EP2275131A2 (de) 2011-01-19
AU2004255456A1 (en) 2005-01-20
JP2011088916A (ja) 2011-05-06
US20070031446A1 (en) 2007-02-08
JP4734241B2 (ja) 2011-07-27
EP1648502A2 (de) 2006-04-26
TW200503752A (en) 2005-02-01

Similar Documents

Publication Publication Date Title
ATE489967T1 (de) Hcv-vakzin
IS7830A (is) Bóluefni gegn lifrarbólgu C veiru (HCV)
MA24422A1 (fr) Vaccin vivant recombinant aviaire, utilisant comme vecteur le virus de la laryngotrachaite infectieuse aviaire.
DE60139127D1 (de) Von hepatitis c virus
WO2006096459A3 (en) Infectious, chimeric hepatitis c virus, methods of producing the same and methods of use thereof
DK0725824T3 (da) Immunodominante humane T-celleepitoper af hepatitis C virus
DK1294893T3 (da) Modifikation af hepatitis B-kerneantigen
WO1993000365A3 (en) Hepatitis c virus (hcv) polypeptides
EA200501689A1 (ru) Соединения в качестве ингибиторов вируса гепатита c
DK1169339T3 (da) Makrocykliske peptider, der inhiberer Hepatitis C-virus NS3-protease
MA24458A1 (fr) Vaccin vivant recombinant aviaire, utilisant comme vecteur le virus de la laryngotracheite infectieuse aviaire.
ATE451119T1 (de) Untereinheit-impfstoff gegen das respiratorische synzytialvirus
HRP20041085B1 (hr) Inhibitori hepatitis c virusa
JP2005501532A5 (de)
DE68903165D1 (de) Rns des genoms des non-a, non-b-hepatitisvirus und antigenisches virales protein.
DE69232906T2 (de) Detektion des Hepatis-C Virus.
NZ518999A (en) Vaccine compositions
EA200300129A1 (ru) Очистка антигенов вируса гепатита b (hbv) для применения в вакцинах
EP1256348A4 (de) Heilmittel gegen hepatitis
EP1399481A4 (de) Rekombinante antikörper gegen infectious bursal disease virus (ibdv)
ATE534666T1 (de) Antikörper gegen den hepatitis c-virus e1e2 komplex und pharmazeutische zusammensetzungen
DK1002092T3 (da) Mimotoper af hypervariabel region 1 af E2-glycoproteinet fra HCV og anvendelser deraf
CU23031A1 (es) Antigeno de superficie del virus de la hepatitis b como inmunopotenciador mucosal, formulaciones resultantes
WO2002026785A3 (de) Cd4+ t-lymphozyten spezifische hepatitis c virus-epitope
RU2004104357A (ru) Вакцинный состав, потенцированный комбинацией днк и антигена